Home / Survodutide 10MG

Survodutide 10MG

The peptide will be provided as lyophilized powder to ensure maximum stability.
Survodutide is a highly promising drug that acts as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor, exerting a wide range of actions. In the treatment of type 2 diabetes and obesity, it can significantly reduce hemoglobin A1c and body weight; it improves cardiovascular risk factors by lowering blood pressure and regulating blood lipids; in the treatment of non-alcoholic steatohepatitis, it can improve hepatic histology, reduce liver fat content, and moderately improve liver fibrosis.
$280
$350
Quantity
ADD TO CART
BUY IT NOW
  • Detail

    Survodutide (BI 456906) 10mg

    Once-Weekly Glucagon / GLP-1 Dual Receptor Agonist  |  Next-Generation Metabolic Research Compound

    GCGR + GLP-1R Co-Agonism · Phase 3 Data Published in NEJM · Research Use Only

    🎯 Dual Co-Agonism

    Simultaneously activates glucagon receptor and GLP-1 receptor — appetite suppression plus energy-expenditure signaling in one molecule.

    📊 Phase 3 NEJM Data

    SYNCHRONIZE-1 reported mean weight reduction up to 16.6% over 76 weeks, published in the New England Journal of Medicine (2026).

    🫁 Fat-Organ Targeting

    Pre-specified analyses showed visceral fat reduction up to 34.0% and liver fat reduction up to 63.1% in the Phase 3 program.

    🧊 Lyophilized Research Grade

    Supplied as a lyophilized powder with lot-specific COA for in-vitro and laboratory research workflows.

    Product Overview

    Survodutide (developmental code BI 456906) is a once-weekly dual glucagon receptor (GCGR) / GLP-1 receptor (GLP-1R) agonist developed jointly by Boehringer Ingelheim and Zealand Pharma. It belongs to the new generation of multi-receptor metabolic compounds: while GLP-1 receptor agonists suppress appetite and slow gastric emptying, adding glucagon-receptor agonism contributes increased energy expenditure and enhanced lipid mobilization — a complementary mechanism that has shown weight-loss results exceeding GLP-1-only therapy in clinical development.

    The development program is among the most closely watched in the metabolic field: the Phase 2 dose-finding trial (published in The Lancet Diabetes & Endocrinology, 2024) demonstrated dose-dependent weight loss, and the global Phase 3 SYNCHRONIZE™ program (SYNCHRONIZE-1 for obesity, SYNCHRONIZE-MASLD for metabolic-dysfunction-associated steatotic liver disease) reported headline results in April 2026, with full data published in the New England Journal of Medicine in June 2026.

    Each vial contains 5mg of survodutide as a lyophilized powder, supplied strictly for in-vitro and laboratory research use only. The compound is investigational and not yet approved by any regulatory authority.　

    Specifications

    Product Name Survodutide
    Developmental Code BI 456906
    Compound Class Dual GCGR / GLP-1R agonist (unimolecular dual-receptor peptide)
    Originators Boehringer Ingelheim & Zealand Pharma (co-development)
    Dosing Regimen (Clinical Program) Once-weekly administration
    Exact Sequence / Molecular Weight Not publicly disclosed by the originators — confirm via your supplier's batch COA / analytical record before use　
    CAS Number Supplier-specific — confirm on batch documentation　
    Net Content 10mg / vial
    Appearance White to off-white lyophilized powder
    Purity ≥ 99% (by HPLC)　
    Storage Store lyophilized at -20°C, protected from light and moisture; refrigerate after reconstitution and use promptly　

    Mechanism: Why Two Receptors?

    Receptor Contribution to the Metabolic Profile
    GLP-1 Receptor Reduces appetite and hunger signals in the brain, slows gastric emptying, increases satiety after meals, and supports glucose-dependent insulin secretion — the established GLP-1 pathway shared by semaglutide and liraglutide.
    Glucagon Receptor Increases energy expenditure and promotes lipid mobilization — including hepatic fat oxidation — complementing the appetite-driven effect of GLP-1 with a genuine energy-burn component. This co-agonism is the rationale for weight loss exceeding GLP-1-only therapy.
    Combined Effect Appetite reduction (eat less) + energy-expenditure increase (burn more) + targeted hepatic/visceral fat mobilization — the three-legged design behind the Phase 3 outcomes.

    Clinical Development Timeline

    📖 Phase 2 — The Lancet Diabetes & Endocrinology, 2024

    Randomised, double-blind, placebo-controlled dose-finding trial in obesity: dose-dependent weight loss with the dual agonist, establishing the dose range carried into Phase 3 (the company reported up to ~19% weight loss in the Phase 2 program).

    📖 Phase 3 SYNCHRONIZE-1 — NEJM, June 2026

    Global, multicentre, randomised, double-blind, placebo-controlled trial (725 participants enrolled) in adults with overweight/obesity without type 2 diabetes: mean weight reduction up to 16.6% over 76 weeks; pre-specified analyses showed visceral fat reduction up to 34.0% and liver fat reduction up to 63.1%, with lean-mass loss minimized. Gastrointestinal events were the main adverse-event class (trial discontinuation due to GI events ~19%).

    📖 SYNCHRONIZE-MASLD — ongoing

    Companion Phase 3 trial evaluating survodutide in metabolic-dysfunction-associated steatotic liver disease — reflecting the compound's distinctive hepatic-fat-mobilization profile.

    Where Survodutide Sits Among Incretin-Based Therapies

    Compound Receptor Profile Status Distinctive Feature
    Survodutide (this product) GCGR + GLP-1R dual Phase 3 (NEJM 2026) Energy expenditure + hepatic/visceral fat targeting
    Semaglutide GLP-1R single Approved Established GLP-1-only profile
    Tirzepatide GIPR + GLP-1R dual Approved GIP co-agonism approach
    Mazdutide GCGR + GLP-1R dual Approved in China (2025) Same dual-class, different molecule
    Cagrilintide (see our listing) Amylin analog (DACRA) Phase 3 / CagriSema program Complementary amylin pathway

    Research Applications & Positioning

    🧫  Dual-receptor pharmacology — GCGR/GLP-1R co-agonism assays, receptor selectivity and potency comparisons.
    ⚖️  Obesity / metabolic research models — body-weight, body-composition and energy-expenditure endpoints.
    🫁  Hepatic-fat and MASLD-related research — lipid-mobilization readouts aligned with the SYNCHRONIZE-MASLD program.
    🧪  Multi-agonist design studies — structural and functional comparison across GLP-1, dual and triple agonist classes.
    📋 Regulatory Status: Survodutide is an investigational compound — it has not been approved for marketing by the FDA, EMA, NMPA or any other regulatory authority as of this listing. All clinical data cited above come from the originators' published trials. This product is supplied solely as a research reagent; purchasers confirm it will not be used for human or animal administration.

    Reconstitution & Handling

    💧  Add sterile or bacteriostatic water slowly down the side of the vial; swirl gently until fully dissolved — do not shake vigorously.
    🧪  Aliquot reconstituted solution to avoid repeated freeze-thaw cycles; label each aliquot with batch, concentration and preparation date.
    🧊  Lyophilized powder: store frozen (-20°C), protected from light and moisture; reconstituted solution: refrigerate and use within your validated stability window.　
    ⚖️  Handle with aseptic technique and appropriate PPE per your laboratory SOP.

    Quality Assurance

    ✔  Lot-specific Certificate of Analysis: HPLC purity confirmation + mass-spectrometry identity verification. Because the originators have not published the exact structure, we strongly recommend confirming identity against your supplier's analytical record before use.

    ✔  Third-party batch testing documentation available upon request.　

    References & Further Reading

    1. Wharton S, et al. Survodutide once weekly for the treatment of adults with overweight or obesity (SYNCHRONIZE-1). N Engl J Med. 2026. (NEJMoa2600751)
    2. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024.
    3. Two randomized phase 3 trials of survodutide (SYNCHRONIZE-1 / SYNCHRONIZE-MASLD): design and rationale. PMC12803687. 2025.
    4. Hope DC, Vincent MR, Tan TMM. Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity. PMC8457634.
    5. ClinicalTrials.gov — NCT06066515: A study to test whether survodutide (BI 456906) helps people living with overweight or obesity to lose weight.
    Disclaimer: This product is intended exclusively for in-vitro laboratory research use. Survodutide is an investigational compound and has not been approved for human or animal use by any regulatory authority. It is not a drug, food, cosmetic, or dietary supplement, and is not intended to diagnose, treat, cure or prevent any disease. Clinical findings cited above are from published trials of the originator product and do not constitute efficacy claims for this research-grade material. All products are supplied strictly for research purposes only.
  • Customer Reviews
    No comments
BACK